Resources
95 Results (showing 51 - 60)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/26/2023 (updated 3/28/2024)
Drake Cooper partnered with JBS International, Inc. (JBS) to help grantees increase their capacity and sustainability through campaign marketing materials built to combat community stigma surrounding substance use disorder (SUD) and OUD.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 3/7/2023 (updated 3/27/2024)
A new article in RHIhub's The Rural Monitor describes the community's understanding of Native culture in Gallup, New Mexico to take an effective, holistic community-wide approach to recovery of SUD. The article highlights a community-wide consortium that works hard to tackle the issue of alcohol and substance use disorders through withdrawal management, peer counseling, assisting with housing, and other services.
Posted 2/28/2023 (updated 3/27/2024)
In November 2022, the FDA issued a letter providing information on the severe ulcerations that can occur from repeated xylazine exposure, withdrawal symptoms, and the interference xylazine can cause on successful treatment. The FDA continues to investigate the source of xylazine in the illicit drug supply. Health care professionals are strongly encouraged to report events in humans associated with xylazine exposure.
Posted 2/1/2023 (updated 3/27/2024)
This study looks at how common the presence of alcohol is in opioid overdose deaths. While there are "waves" of the opioid crisis, the authors studied how alcohol affect individuals in this fourth wave as it is characterized by opioid-stimulant polysubstance use.
Posted 1/24/2023 (updated 3/27/2024)
This webinar will introduce the newest RCORP program cohorts to the RCOEs, Fletcher Group, University of Rochester, and University of Vermont. These three cooperative agreements are charged with supporting the identification, translation, dissemination, and implementation of evidence-based programs and best practices, in addition to providing specialized TA to RCORP recipients and other rural providers.
Posted 6/2/2023 (updated 3/27/2024)
Behavioral health care encompasses a wide variety of interventions delivered by many different types of providers. Although there is a call for expanding direct or indirect behavioral health service systems to care for those affected, in the U.S., nearly all these providers are in short supply.